Bausch + Lomb recalls lenses used in cataract surgery due to inflammatory reactions
Bausch + Lomb recalls lenses used in cataract surgery due to inflammatory reactions
Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S. Food and Drug Administration's website.
The company recalled all lots of its enVista Aspire, enVista Aspire Toric, enVista Envy and enVista Envy Toric intraocular lenses. Also included are the enVista monofocal and enVista monofocal Toric lenses, the company said.
The company recalled the products after receiving an increased number of reports of toxic anterior segment syndrome (TASS), an inflammatory reaction of the anterior segment of the eye.
'This action was taken after the company received reports of complications, the cause of which could not immediately be explained,' Bausch + Lomb said in its announcement.
Brent Saunders, chairman and CEO, Bausch + Lomb, said in the announcement that patient safety is the company's main concern.
'Surgeons and patients trust Bausch + Lomb, and I believe that this voluntary recall is the best thing we can do to honor that trust,' Saunders said.
Read more: USA TODAY's recall database
What is an intraocular lens?
An intraocular lens, also called an IOL, is a small, artificial lens doctors surgically add to the eye. Doctors remove the eye's natural lens during surgery and then replace it with the intraocular lens, according to the American Academy of Ophthalmology.
The lens bends light rays that enter the eye, helping patients to see, the academy said. The natural lenses are clear but those suffering from cataracts have cloudy lenses. The cloudiness causes patients to have blurry, hazy or less colorful vision.
Doctors who treat these patients remove the cloudy lenses and replace them with the clear intraocular lenses like the ones Bausch + Lomb manufactures.
The intraocular lenses are made of silicone, acrylic, or other plastics and are coated in material to protect the eyes from the sun's ultraviolet rays. Similar to prescription glasses and contact lenses, intraocular lenses come in different strengths, the academy said.
According to the academy, intraocular lenses function in different ways to address a range of vision issues.
What lenses are recalled?
Recalled lenses include:
enVista Monofocal – All models starting with EE
enVista Aspire IOL – All models starting with EA
enVista Envy IOL – All models starting with EN
enVista Monofocal Toric IOL – All models starting with ETE
enVista Aspire Toric IOL – All models starting with ETA
enVista Envy Toric IOL – All models starting with ETN
What is toxic anterior segment syndrome?
Bausch + Lomb issued the recall after it received reports of toxic anterior segment syndrome, also called TASS, according to the announcement.
TASS is a complication in cataract surgeries that involves an inflammatory reaction inside the eye. The complication typically occurs 12 to 48 hours after eye surgery, the company said. The condition can be caused by detergents or disinfectants on surgical instruments, improperly mixed solutions, preservatives-containing medications injected into the eye, or endotoxins in intraocular lens implants, the company said.
According to the company, all enVista TASS cases reported to Bausch + Lomb were treated quickly and improved. None of these cases led to the lenses having to be removed.
'These reports represent only 1-2% of implanted lenses, with a positive prognosis for everyone involved,' Saunders said. 'We look forward to identifying a root cause and bringing the enVista platform back to market.'
What should I do if I am having complications?
The company said it is already communicating with eyecare professionals and recommends that they keep an eye on cataract surgery patients for at least 48 hours after surgery.
Patients who are having complications should contact their doctors immediately.
To report issues, contact Bausch + Lomb Customer Service at 1-800-338-2020, option 1, or submit a report to FDA's MedWatch program.
Saleen Martin is a reporter on USA TODAY's NOW team. She is from Norfolk, Virginia – the 757. Email her at sdmartin@usatoday.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
24 minutes ago
- Business Upturn
SEPC secures Rs 650 crore solar EPC contract from Parmeshi Urja
By Aman Shukla Published on June 12, 2025, 15:55 IST SEPC Limited (NSE: SEPC | BSE: 532945), a leading player in the Engineering, Procurement, and Construction (EPC) space, has been awarded a prestigious contract worth ₹650 crore by Parmeshi Urja Ltd, a Kolkata-based subsidiary of India Power Corporation Limited. The project entails the full EPC scope — including Design, Engineering, Supply, Installation, Testing, and Commissioning — of a 133 MW Solar Power Project. The solar infrastructure will be spread across four key districts in Maharashtra: Sambhaji Nagar, Dhule, Solapur, and Nanded. This green energy initiative falls under the Government of India's PM-KUSUM Yojana, which aims to boost solar adoption for agricultural and rural development. With an estimated execution timeline of 12 to 18 months, the project is a strategic leap for SEPC, marking its return to the renewable energy sector. The company, known for its past projects in Wind, Biomass, and Thermal power, is poised to deliver high-quality, large-scale infrastructure solutions. This major order almost doubles SEPC's domestic order book and strengthens its portfolio across the renewable energy domain. It also reinforces SEPC's commitment to supporting India's clean energy mission and showcases its expertise in executing technically complex infrastructure projects across multiple regions. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
San Francisco Chronicle
32 minutes ago
- San Francisco Chronicle
A major wine company is exiting California. Here's what it means
Alcohol distribution does not sound like an exciting topic, but it's suddenly the hot gossip within California wine circles. Republic National Distributing Co., the nation's second-largest alcohol wholesaler, announced last week that it will no longer do business in California after Sept. 2. It's sent more than 2,500 beverage brands scrambling to find a new distributor in the state. This reshuffling has generated so much attention largely because it looks like a dire warning for an industry already known to be in peril. If a wholesale behemoth is simply opting out of the largest wine market in the U.S. — if it would rather leave than try to compete — that seems like confirmation that the alcohol industry's downturn has not reached its bottom. While the Grand Prairie, Texas-based Republic National has not suggested that politics played a role in the decision, the news also may be resonating so widely in part because of the narrative it presents: A Texas company wants nothing to do with California. CEO Bob Hendrickson cited 'rising operational costs, industry head winds, and supplier changes' as reasons for the move. The latter is what everyone in the wine industry seems to be discussing. Some of Republic National's most important brands have defected lately to other distributors, especially to the beer-focused Reyes Beverage Group. Since the beginning of the year, the company has lost the right to sell top-selling spirits including Tito's, High Noon, Cutwater Spirits and Jack Daniel's, among many others. The loss of those brands had to be a major financial blow to Republic National. Why they all left, and all at once, is unclear. VinePair's Dave Infante posited that it was the result of Reyes' quest to increase its spirits portfolio after a change in California law made it easier for beer wholesalers to sell liquor. 'It left everybody in the lurch,' said John Buehler, owner of Napa Valley's Buehler Vineyards, where wholesale purchases drive 80% of the business. 'It was really such short notice.' Although Republic National continues to sell his wines in a few other states, he'll need to find a new California distributor. Many wineries and distilleries will now try to jump onto the lists of the other two big dogs, Southern Glazer's Wine and Spirits or Breakthru Beverage Group. The Napa-based importer Wilson Daniels has already announced it's bringing its book of prestigious wines like Burgundy's Domaine de la Romanee-Conti and Piedmont's Gaja to Breakthru, while Treasury Americas president Ben Dollard said he's still 'evaluating alternative arrangements' for wineries including Beaulieu, Frank Family and Daou. Other producers will look to smaller distributors, like Chambers & Chambers or Skurnik Wines & Spirits, for their California sales. But in a contracting wine market, there may not be room for everybody on those lifeboats. 'It's going to be a thinning of the herd,' Buehler said. 'The ankle biters that were in that portfolio, the little guys — there's going to be a lot of collateral damage.' Republic National had only recently increased its presence in the Golden State when it completed the purchase of major California distributor Young's Market Co. in 2022. The industry analyst Impact Databank estimated the company's sales that year at $2.8 billion in California alone. Despite that considerable power, however, Buehler — who had been with Young's since 1992 and moved to Republic National as a result of that acquisition — said that Republic National consistently 'underperformed' for him in terms of sales. He now regrets waiting so long to find a new distributor. 'I think I should have seen the writing on the wall. You lose these suppliers, and you're not attracting any new suppliers,' he said. Still, 'I had no idea that they were going to close up shop.' At least Republic National appears to still be selling his wine ahead of the September shutdown date. 'I keep getting purchase orders,' Buehler said, 'so I guess it's business as usual.'
Medscape
32 minutes ago
- Medscape
Family Ties May Shape Hashimoto Thyroiditis Risk
The odds of developing Hashimoto thyroiditis (HT) were significantly elevated in first-, second-, and third-degree relatives of patients with HT, with female relatives having a disproportionately higher likelihood. Of note, the odds of developing HT were elevated among spouses of patients. METHODOLOGY: Relatives of patients with HT are at an increased risk for HT; however, studies have primarily focused on first-degree relatives and often employed very small sample sizes. Researchers conducted a retrospective case-control study using genealogical and medical data from a Utah-based database (1996-2021) to estimate the risk for HT in relatives across various degrees of relatedness. They included 92,405 adult HT probands (73% women; 96% White individuals) and 184,810 matched control individuals, along with 2,960,650 first-, second-, and third-degree relatives of HT probands and 5,730,159 relatives of control individuals. TAKEAWAY: Relatives of patients with HT were at an increased risk for the condition, with the highest odds observed for first-degree relatives (odds ratio [OR], 1.77; 95% CI, 1.74-1.80), followed by second-degree (OR, 1.23; 95% CI, 1.22-1.27) and third-degree (OR, 1.11; 95% CI, 1.10-1.12) relatives. The risk for HT was an additional 2.2- to 2.6-fold higher in female relatives of patients with HT than overall estimates, across all degrees of relatedness. Among first-degree relatives, sons of men with HT had a markedly elevated risk for HT (OR, 2.36; 95% CI, 2.10-2.65). Wives of men with HT and husbands of women with HT were at an increased likelihood of developing HT, suggesting the effect of a shared environment. IN PRACTICE: 'These findings also have clinical implications, as understanding familial clustering of HT can help healthcare providers identify individuals at higher risk, especially those with affected FDRs [first-degree relatives]. This knowledge could lead to earlier monitoring and intervention, improving disease management,' the authors of the study wrote. SOURCE: This study was led by Melissa Bujnis, PhD, Department of Human Genetics, University of Utah, Salt Lake City. It was published online in The Journal of Clinical Endocrinology & Metabolism . LIMITATIONS: Reliance on diagnostic codes may have introduced misclassification bias, particularly in cases of transient hypothyroidism or misdiagnosed HT. Variations in diagnostic practices across clinics may have introduced heterogeneity in the sample. Individuals with a family history of HT might be more likely to receive diagnosis or seek medical attention, potentially introducing ascertainment bias. DISCLOSURES: Partial support for the datasets in the database was provided by the University of Utah, Huntsman Cancer Institute, National Institutes of Health (NIH). This study received support from NIH, NCRR, and Utah Department of Health and Human Services and the University of Utah. The authors reported no relevant conflicts of interest.
